Aprinoia Therapeutics (Aprinoia Therapeutics) Equity-to-Asset : -5.66 (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aprinoia Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-81.93 Mil. Aprinoia Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $14.48 Mil. Therefore, Aprinoia Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was -5.66.

The historical rank and industry rank for Aprinoia Therapeutics's Equity-to-Asset or its related term are showing as below:

APRI's Equity-to-Asset is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Equity-to-Asset only.

Aprinoia Therapeutics Equity-to-Asset Historical Data

The historical data trend for Aprinoia Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Equity-to-Asset Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Equity-to-Asset

-3.81

-13.37

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Equity-to-Asset	-3.81	-	-13.37	-5.66

Competitive Comparison of Aprinoia Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Aprinoia Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's Equity-to-Asset falls into.

Aprinoia Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Aprinoia Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	-75.45	/	5.643
	=	-13.37

Aprinoia Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-81.932	/	14.476
	=	-5.66

Aprinoia Therapeutics (NAS:APRI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Aprinoia Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines